PURPOSE: To learn whether an antecedent hematologic disorder (AHD) is associated with additional risk in patients with therapy-related acute myeloid leukemia (t-AML). PATIENTS AND METHODS: We reviewed data of 301 patients with newly diagnosed t-AML who sought care from January 2000 to January 2014 (183 t-AML without AHD, 118 t-AML with AHD). Overall, median follow-up was 44 months. RESULTS: The primary malignancy was non-Hodgkin lymphoma in 92 (31%), breast cancer in 80 (27%), and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months and 29 months, respectively (P = .032); median overall survival (OS) was 8 months and 8 months, respectively (P = .53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, nonfavorable cytogenetics, and lack of response as adverse factors. CONCLUSION: The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS.
PURPOSE: To learn whether an antecedent hematologic disorder (AHD) is associated with additional risk in patients with therapy-related acute myeloid leukemia (t-AML). PATIENTS AND METHODS: We reviewed data of 301 patients with newly diagnosed t-AML who sought care from January 2000 to January 2014 (183 t-AML without AHD, 118 t-AML with AHD). Overall, median follow-up was 44 months. RESULTS: The primary malignancy was non-Hodgkin lymphoma in 92 (31%), breast cancer in 80 (27%), and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months and 29 months, respectively (P = .032); median overall survival (OS) was 8 months and 8 months, respectively (P = .53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, nonfavorable cytogenetics, and lack of response as adverse factors. CONCLUSION: The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS.
Authors: L Pagana; A Pulsoni; M E Tosti; G Avvisati; L Mele; M Mele; B Martino; G Visani; R Cerri; E Di Bona; R Invernizzi; A Nosari; M Clavio; B Allione; P Coser; A Candoni; A Levis; A Camera; L Melillo; G Leone; F Mandelli Journal: Br J Haematol Date: 2001-01 Impact factor: 6.998
Authors: D A Carney; D A Westerman; C S Tam; A Milner; H M Prince; M Kenealy; M Wolf; E H Januszewicz; D Ritchie; N Came; J F Seymour Journal: Leukemia Date: 2010-10-21 Impact factor: 11.528
Authors: J E Anderson; T A Gooley; G Schoch; C Anasetti; W I Bensinger; R A Clift; J A Hansen; J E Sanders; R Storb; F R Appelbaum Journal: Blood Date: 1997-04-01 Impact factor: 22.113
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: Gautam Borthakur; E Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian Journal: Cancer Date: 2009-07-15 Impact factor: 6.860
Authors: Alessandro Pulsoni; Livio Pagano; Francesco Lo Coco; Giuseppe Avvisati; Luca Mele; Eros Di Bona; Rosangela Invernizzi; Franco Leoni; Filippo Marmont; Alfonso Mele; Lorella Melillo; Anna Maria Nosari; Enrico Maria Pogliani; Marco Vignetti; Giuseppe Visani; Vittorina Zagonel; Giuseppe Leone; Franco Mandelli Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544
Authors: Vijaya R Bhatt; Valerie Shostrom; Sarah A Holstein; Zaid S Al-Kadhimi; Lori J Maness; Ann Berger; James O Armitage; Krishna Gundabolu Journal: Clin Lymphoma Myeloma Leuk Date: 2020-02-04
Authors: María Del Carmen Vicente-Ayuso; María García-Roa; Ataúlfo González-Fernández; Ana María Álvarez-Carmona; Celina Benavente-Cuesta; Marta Mateo-Morales; Cristina Pérez-López; Ascensión Peña-Cortijo; Marta Polo Zarzuela; Laura Gutiérrez; Rafael Martínez-Martínez Journal: Hematol Rep Date: 2017-09-27